Emerging drugs for irritable bowel syndrome

Bibliography

• Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2(6138):653-4
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
   PubMed Web of Science ®Google Scholar
• Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17(5):643-50
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119(3):654-60
   PubMed Web of Science ®Google Scholar
• Smith GD, Steinke DT, Kinnear M, A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract 2004;54(504):503-7
   PubMed Web of Science ®Google Scholar
• Akehurst RL, Brazier JE, Mathers N, Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002;20(7):455-62
   PubMed Web of Science ®Google Scholar
• Houghton LA, Atkinson W, Whitaker RP, Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003;52(5):663-70
   PubMed Web of Science ®Google Scholar
• Houghton LA, Atkinson W, Lockhart C, Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterol Motil 2007;19(9):724-31
   PubMed Web of Science ®Google Scholar
• Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42(6):845-9
   PubMed Web of Science ®Google Scholar
• Harvey RF, Read AE. Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable-bowel syndrome. Lancet 1973;1(7793):1-3
   PubMed Web of Science ®Google Scholar
• Houghton LA, Jackson NA, Whorwell PJ, Morris J. Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol 2000;95(9):2296-300
   PubMed Web of Science ®Google Scholar
• Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002;50(4):471-4
   PubMed Web of Science ®Google Scholar
• Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42(Suppl 17):41-7
   PubMed Web of Science ®Google Scholar
• Spiller RC. Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2004;2(6):445-55
   PubMed Web of Science ®Google Scholar
• O'Mahony L, McCarthy J, Kelly P, Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128(3):541-51
   PubMed Web of Science ®Google Scholar
• Trimble KC, Farouk R, Pryde A, Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995;40(8):1607-13
   PubMed Web of Science ®Google Scholar
• Kwan CL, Diamant NE, Mikula K, Davis KD. Characteristics of rectal perception are altered in irritable bowel syndrome. Pain 2005;113(1-2):160-71
   PubMed Web of Science ®Google Scholar
• McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci 1993;38(10):1773-82
   PubMed Web of Science ®Google Scholar
• Evans PR, Bak YT, Shuter B, Gastroparesis and small bowel dysmotility in irritable bowel syndrome. Dig Dis Sci 1997;42(10):2087-93
   PubMed Web of Science ®Google Scholar
• Chey WY, Jin HO, Lee MH, Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96(5):1499-506
   PubMed Web of Science ®Google Scholar
• Miller V, Hopkins L, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2(12):1064-8
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Spiegel BM, Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313
   PubMed Web of Science ®Google Scholar
• Quartero AO, Meineche-Schmidt V, Muris J, Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005;18(2):CD003460
   Google Scholar
• Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am 2005;34(2):319-35, viii
   PubMed Web of Science ®Google Scholar
• Lesbros-Pantoflickova D, Michetti P, Fried M, Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(11-12):1253-69
   PubMed Web of Science ®Google Scholar
• Bijkerk CJ, Muris JW, Knottnerus JA, Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19(3):245-51
   PubMed Web of Science ®Google Scholar
• Van Outryve M, Milo R, Toussaint J, “Prokinetic” treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991;13(1):49-57
   PubMed Web of Science ®Google Scholar
• Schutze K, Brandstatter G, Dragosics B, Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997;11(2):387-94
   PubMed Web of Science ®Google Scholar
• Barbey JT, Lazzara R, Zipes DP. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 2002;7(2):65-76
   PubMedGoogle Scholar
• Camilleri M, Chey WY, Mayer EA, A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161(14):1733-40
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Olden KW, Ameen VZ, Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004;2(8):675-82
   PubMed Web of Science ®Google Scholar
• Novick J, Miner P, Krause R, A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16(11):1877-88
   PubMed Web of Science ®Google Scholar
• Tack J, Muller-Lissner S, Bytzer P, A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54(12):1707-13
   PubMed Web of Science ®Google Scholar
• Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007;17(4):CD003960
   Google Scholar
• Available from: http://www.fda.gov/cder/drug/infopage/zelnorm/default.htm. [Cited 2007]
   Google Scholar
• Available from: http://www.fda.gov/cder/drug/infopage/lotronex/lotronex.htm. [Cited]
   Google Scholar
• Available from: http://www.nature.com/nrd/journal/v5/n2/full/nrd1961.html.
   Google Scholar
• Available from: http://www.pharmaprojects.com/
   Google Scholar
• Available from: http://www.nature.com/nrd/journal/v5/n2/full/nrd1961.html.
   Google Scholar
• Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132(1):397-414
   PubMed Web of Science ®Google Scholar
• Beattie DT, Smith JA. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008;377(3):181-203
   PubMed Web of Science ®Google Scholar
• Available from: http://www.alizyme.com/alizyme/products/renzapride/
   Google Scholar
• Briejer MR, Bosmans JP, Van Daele P, The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423(1):71-83
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44(5):682-6
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-60
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16(7):1347-56
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358(22):2344-54
   PubMed Web of Science ®Google Scholar
• Tack J, Van Outryve M, Beyens G, Prucalopride (resolor(R)) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58(3):357-65
   PubMed Web of Science ®Google Scholar
• Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554(2-3):98-105
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29(3):315-28
   PubMed Web of Science ®Google Scholar
• Dwight E, Moulin AR, Kerstens R, Vandeplassche L. Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in patients with opioid-induced constipation. Gastroenterology 2008;134(4):A-92
   Google Scholar
• Smith JA, Beattie DT, Marquess D, The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378(1):125-37
   PubMed Web of Science ®Google Scholar
• Beattie DT, Armstrong SR, Shaw JP, The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378(1):139-47
   PubMed Web of Science ®Google Scholar
• Camilleri M, McKinzie S, Sweetser S, Dose-related effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers. Neurogastroenterol Motil 2008;20(S 2):6
   Google Scholar
• Goldberg MR, Li Y-P, Pitzer K, TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008;134(4):A-545
   Google Scholar
• Goldberg M, Garofalo B, Valmonte A, In patients with chronic constipation, TD-5108, a selective 5-HT4 agonist with high intrinsic activity, relieves straining and bloating, normalizes stool consistency and reduces laxative use. Gastroenterology 2008;134(4):A-547
   Google Scholar
• Camilleri M, Vazquez-Roque MI, Burton D, Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19(1):30-8
   PubMed Web of Science ®Google Scholar
• Coleman NS, Marciani L, Blackshaw E, Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 2003;18(10):1039-48
   PubMed Web of Science ®Google Scholar
• Fujita T, Yokota S, Sawada M, Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther 2005;30(6):611-22
   PubMed Web of Science ®Google Scholar
• Paterson WG, Ford D, Ganguli SC, A novel, oral 5HT3 partial agonist, DDP-733, improves overall response in patients with irritable bowel syndrome and constipation (IBS-C): a randomized, double-blind, placebo-controlled, parallel-group, dose ranging study. Gastroenterology 2008;134(s):A456-7
   Google Scholar
• Available from: http://www.clinicaltrials.gov/ct/show/NCT00547469?order=1.
   Google Scholar
• Naliboff BD, Wu SM, Pham Q. Clinical considerations in the treatment of chronic pain with opiates. J Clin Psychol 2006;62(11):1397-408
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-8S
   PubMed Web of Science ®Google Scholar
• Rogers M, Cerda JJ. The narcotic bowel syndrome. J Clin Gastroenterol 1989;11(2):132-5
   PubMed Web of Science ®Google Scholar
• Bradesi S, Herman J, Mayer EA. Visceral analgesics: drugs with a great potential in functional disorders? Curr Opin Pharmacol 2008;8(6):697-703
   PubMed Web of Science ®Google Scholar
• Barber A, Bartoszyk GD, Bender HM, A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994;113(4):1317-27
   PubMed Web of Science ®Google Scholar
• Schreiber R, Bartoszyk GD, Kunzelmann K. The kappa-opioid receptor agonist asimadoline inhibits epithelial transport in mouse trachea and colon. Eur J Pharmacol 2004;503(1-3):185-90
   PubMed Web of Science ®Google Scholar
• Larsson MH, Bayati A, Lindstrom E, Larsson H. Involvement of kappa-opioid receptors in visceral nociception in mice. Neurogastroenterol Motil 2008;20(10):1157-64
   PubMed Web of Science ®Google Scholar
• Delvaux M, Beck A, Jacob J, Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(2):237-46
   PubMed Web of Science ®Google Scholar
• Szarka LA, Camilleri M, Burton D, Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007;5(11):1268-75
   PubMed Web of Science ®Google Scholar
• Mangel AW, Bornstein JD, Hamm LR, Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28(2):239-49
   PubMed Web of Science ®Google Scholar
• Floyd BN, Camilleri M, Busciglio I, Effect of a kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers. Neurogastroenterol Motil 2009;21(3):281-90
   PubMed Web of Science ®Google Scholar
• Horvath EJ, Horvath K, Hamori T, Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol 2000;60(4):309-42
   PubMed Web of Science ®Google Scholar
• Horvath EJ, Palkovits M, Lenkei Z, Autoradiographic localization and quantitative determination of specific binding sites of anxiolytic homophthalazines (formerly called 2,3-benzodiazepines) in the striato-pallido-nigral system of rats. Brain Res Mol Brain Res 1994;22(1-4):211-8
   PubMedGoogle Scholar
• Leventer SM, Keogh JC, Raudibaugh K, The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol 2004;99(10):S279
   Web of Science ®Google Scholar
• Leventer SM, Raudibaugh K, Frissora CL, Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27(2):197-206
   PubMed Web of Science ®Google Scholar
• Liddle RA. Cholecystokinin cells. Annu Rev Physiol 1997;59:221-42
   PubMed Web of Science ®Google Scholar
• Noble F, Wank SA, Crawley JN, International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51(4):745-81
   PubMed Web of Science ®Google Scholar
• Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994;15(4):731-55
   PubMed Web of Science ®Google Scholar
• Kellow JE, Miller LJ, Phillips SF, Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide. Am J Physiol 1987;252(3 Pt 1):G345-56
   PubMed Web of Science ®Google Scholar
• Cremonini F, Camilleri M, McKinzie S, Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100(3):652-63
   PubMed Web of Science ®Google Scholar
• Meyer BM, Werth BA, Beglinger C, Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 1989;2(8653):12-5
   PubMed Web of Science ®Google Scholar
• Rettenbacher M, Reubi JC. Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch Pharmacol 2001;364(4):291-304
   PubMed Web of Science ®Google Scholar
• Varga G, Balint A, Burghardt B, D'Amato M. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. Br J Pharmacol 2004;141(8):1275-84
   PubMed Web of Science ®Google Scholar
• Bonnafous C, Griffin PH, Schneier H. Influence of dexloxiglumide on visceromotor and pain response induced by recta distension in rats. Gastroenterology 2002;122(4):S1
   Google Scholar
• Whorwell PJ, D'Amato M, Giacovelli G, A phase III, 6-month, double-blind, placebo-controlled, randomized withdrawal trial of the selective CCK-1 antagonist dexloxiglumide in constipation -predominant IBS: the DARWIN study. Gastroenterology 2008;134(4 Suppl 1):A157
   Web of Science ®Google Scholar
• Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 1999;81(1-3):25-39
   PubMed Web of Science ®Google Scholar
• Andresen V, Camilleri M, Busciglio IA, Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133(3):761-8
   PubMed Web of Science ®Google Scholar
• Johnston J, MacDougall J, Lavins B, Linaclotide significantly improved abdominal pain, constipation and global assessments in adults with irritable bowel syndrome with constipation: Results from a Large Twelve-Week, Randomized, Double-Blind, Placebo-Controlled Study. Am J Gastroenterol 2008;103:S460
   Web of Science ®Google Scholar
• Johnston J, Kurtz CB, Drossman DA, Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104(1):125-32
   PubMed Web of Science ®Google Scholar
• Lembo AJ, MacDougall JE, Lavins BJ, Linaclotide significantly improved bowel habits and relieved abdominal symptoms in adults with chronic constipation: Data from a Large 4-Week, Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology 2008;135(1):295
   Google Scholar
• Ustinova E, Reza T, Currie M, Pezzone M. Oral Cyclic Guanosine Monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis. Am J Gastroenterol 2008;103:S187
   Web of Science ®Google Scholar
• Bueno L, Eutamen H, Gillet M, Effect of oral cyclic GMP on TNBS-induced colitis and visceral hypersensitivity in rats. Am J Gastroenterol 2008;103:S458
   PubMed Web of Science ®Google Scholar
• Busby RW, Bryant AP, Cordero EA, The molecular target of MD-1100 is Guanylate Cyclase C (GC-C), an apical receptor on intestinal epithelial cells. Gastroenterol Clin North Am 2005;128(4 Suppl 2):A464
   Google Scholar
• Elena Ustinova AB, Reza T, Currie M, Medicine: oral Cyclic Guanosine Monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis. American J Gastaroenterology 2008;103(S):187 [Abstract]
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=linaclotide.
   Google Scholar
• Available from: http://www.synergybio.net/sp304.htm.
   Google Scholar
• Suzuki M, Morita T, Iwamoto T. Diversity of Cl(-) channels. Cell Mol Life Sci 2006;63(1):12-24
   PubMed Web of Science ®Google Scholar
• Blikslager AT, Moeser AJ, Gookin JL, Restoration of barrier function in injured intestinal mucosa. Physiol Rev 2007;87(2):545-64
   PubMed Web of Science ®Google Scholar
• Moeser AJ, Nighot PK, Engelke KJ, Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007;292(2):G647-56
   PubMed Web of Science ®Google Scholar
• Moeser AJ, Nighot PK, Roerig B, Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine. World J Gastroenterol 2008;14(39):6012-7
   PubMed Web of Science ®Google Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25(11):1351-61
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103(1):170-7
   PubMed Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27(8):685-96
   PubMed Web of Science ®Google Scholar
• Chey WD, Scott C, Panas RM, Ueno R. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 2008;134(4 Suppl 1):A-215
   PubMed Web of Science ®Google Scholar
• Chey WD, Scott C, Panas RM, Ueno R. What symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation: data from two multicenter, randomized, placebo-controlled trials. Gastroenterology 2008;134(4 Suppl 1):A-28
   Google Scholar
• Chey WD, Panas RM, Wahle A, Ueno R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal study. Gastroenterology 2008;134(4 Suppl 1):A-401
   Google Scholar
• Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995;26(5):911-44
   PubMedGoogle Scholar
• Lecci A, Capriati A, Maggi CA. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 2004;141(8):1249-63
   PubMed Web of Science ®Google Scholar
• Desvignes C, Rouquier L, Souilhac J, Control by tachykinin NK(2) receptors of CRF(1) receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig. Neuropeptides 2003;37(2):89-97
   PubMed Web of Science ®Google Scholar
• Available from: http://www.menarini.com/menarini/r_d/aree_terapeutiche/development_projects/nepadutant.
   Google Scholar
• Houghton LA, Cremonini F, Camilleri M, Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 2007;19(9):732-43
   PubMed Web of Science ®Google Scholar
• Dukes GE, Sanger GJ, Ameen VA, Lack of effect of the NK3 receptor antagonist, talnetant SB223242 on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled dose rnaging trials. Gastroenterology 2007;132(4 Suppl 2):A 60
   Google Scholar
• Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991;43(4):425-73
   PubMed Web of Science ®Google Scholar
• Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990;15(2):71-100
   PubMed Web of Science ®Google Scholar
• Tache Y, Monnikes H, Bonaz B, Rivier J. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci 1993;697:233-43
   PubMed Web of Science ®Google Scholar
• Sagami Y, Shimada Y, Tayama J, Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53(7):958-64
   PubMed Web of Science ®Google Scholar
• Sweetser S, Camilleri M, Linker Nord SJ, Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 2009;296(6):G1299-306
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=GW876008.
   Google Scholar
• Available from: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.
   Google Scholar
• Malinen E, Rinttila T, Kajander K, Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100(2):373-82
   PubMed Web of Science ®Google Scholar
• Kim HJ, Vazquez Roque MI, Camilleri M, A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17(5):687-96
   PubMed Web of Science ®Google Scholar
• McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14(17):2650-61
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Altringer L, Morel J, Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101(7):1581-90
   PubMed Web of Science ®Google Scholar
• Kim HJ, Camilleri M, McKinzie S, A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17(7):895-904
   PubMed Web of Science ®Google Scholar
• Guyonnet D, Chassany O, Ducrotte P, Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26(3):475-86
   PubMed Web of Science ®Google Scholar
• Agrawal A, Houghton LA, Morris J, Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;29(1):104-17
   PubMed Web of Science ®Google Scholar
• Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. BMJ 2006;332(7536):280-3
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson OS, Levy RR, Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007;102(12):2767-76
   PubMed Web of Science ®Google Scholar
• Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008;135(6):1877-91
   PubMed Web of Science ®Google Scholar
• Kapeller J, Houghton LA, Monnikes H, First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008;17(19):2967-77
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, Zinsmeister AR, Mitochondrial DNA, gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders. Am J Physiol Gastrointest Liver Physiol 2009;296(3):G510-G516
   PubMed Web of Science ®Google Scholar
• Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 2008;28(46):11768-77
   PubMed Web of Science ®Google Scholar
• Cole JA, Rothman KJ, Cabral HJ, Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol 2006;6:26
   PubMed Web of Science ®Google Scholar
• Saito YA, Strege PR, Tester DJ, Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol 2009;296(2):G211-8
   PubMed Web of Science ®Google Scholar
• Akbar A, Yiangou Y, Facer P, Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57(7):923-9
   PubMed Web of Science ®Google Scholar
• Chan CL, Facer P, Davis JB, Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003;361(9355):385-91
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, McKinzie S, Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol 2008;294(1):G13-9
   PubMed Web of Science ®Google Scholar
• Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004;141(8):1335-45
   PubMed Web of Science ®Google Scholar
• Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2008;29(2):192-200
   PubMed Web of Science ®Google Scholar
• Bueno L. Protease activated receptor 2: a new target for IBS treatment. Eur Rev Med Pharmacol Sci 2008;12(Suppl 1):95-102
   PubMed Web of Science ®Google Scholar
• Vergnolle N. Modulation of visceral pain and inflammation by protease-activated receptors. Br J Pharmacol 2004;141(8):1264-74
   PubMed Web of Science ®Google Scholar
• Jackson JL, O'Malley PG, Tomkins G, Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108(1):65-72
   PubMed Web of Science ®Google Scholar